Alchemia raises $5m in share purchase plan
Wednesday, 14 December, 2005
Brisbane biopharma Alchemia (ASX:ACL) has successfully raised AUD$5 million, closing its share purchase plan heavily oversubscribed. Earlier this month the company raised $14.6 million through a share placement. The funds will be used to accelerate Alchemia's drug discovery program, specifically to progress anti-cancer drug candidate ACL16907 from preclinical status to the completion of phase II clinical trials in 2008, and to advance an eye-disease candidate for age-related macular degeneration to the end of phase I clinical trials by 2007-08.
It will also be used to help identify new preclinical candidates using Alchemia's drug discovery platform
The offer of up to 4,545 shares at $1.10 per share was made to all registered shareholders in Australia and New Zealand on November 3, and taken up by more than 65 per cent of eligible shareholders. At time of writing Alchemia shares were trading at $1.19.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
